Chemed (CHE) Receives a Buy from Jefferies
Jefferies analyst Brian Tanquilut maintained a Buy rating on Chemed today and set a price target of $550.00.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
According to TipRanks, Tanquilut is a 4-star analyst with an average return of 5.7% and a 53.25% success rate. Tanquilut covers the Healthcare sector, focusing on stocks such as Chemed, Cardinal Health, and HCA Healthcare.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Chemed with a $574.25 average price target.
Based on Chemed’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $624.9 million and a net profit of $64.24 million. In comparison, last year the company earned a revenue of $606.18 million and had a net profit of $75.78 million
Based on the recent corporate insider activity of 30 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of CHE in relation to earlier this year. Last month, Kevin J. McNamara, the President & CEO of CHE sold 2,000.00 shares for a total of $875,100.00.
Read More on CHE:
